Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach.
Fontanella C, Giorgi CA, Russo S, Angelini S, Nicolardi L, Giarratano T, Frezzini S, Pestrin M, Palleschi D, Bolzonello S, Parolin V, Haspinger ER, De Rossi C, Greco F, Gerratana L.
Fontanella C, et al. Among authors: palleschi d.
Crit Rev Oncol Hematol. 2022 Dec;180:103848. doi: 10.1016/j.critrevonc.2022.103848. Epub 2022 Oct 17.
Crit Rev Oncol Hematol. 2022.
PMID: 36257536
Free article.
Review.